For decades, the global botanical ingredients industry operated on a straightforward model: source raw plant material from tropical and subtropical regions where labour is inexpensive and biodiversity is abundant, process it through a chain of intermediaries, and deliver it to European manufacturers for formulation. The primary selection criteria were price and availability. The system worked well enough when nobody looked too closely at what happened between the field and the factory. That model is now under structural pressure from multiple directions, and the companies that depend on it are beginning to respond. What is emerging is not a temporary shift but a structural realignment of how multinational cosmetics and pharmaceutical companies think about botanical supply security.
Three forces converging
The first force is climate disruption in traditional growing regions. Countries that supply a significant share of the world’s botanical raw materials have experienced consecutive years of severe heat waves, erratic monsoon patterns, and intensifying cyclone seasons. These events directly impact crop yields, quality consistency, and supply predictability for commercially important medicinal plant species. This is not isolated. It represents a pattern of increasing volatility that makes long-term supply planning unreliable.
The second force is regulatory. The Nagoya Protocol, actively enforced across EU member states through Regulation 511/2014, requires companies to demonstrate that genetic resources were obtained with prior informed consent and that benefit-sharing obligations are met. For botanical ingredients sourced through multi-intermediary chains originating in signatory countries, establishing this documentation trail is difficult. The compliance burden falls on the European buyer, and the penalties for non-compliance include administrative sanctions and reputational damage.
The third force is reporting. The EU Corporate Sustainability Reporting Directive requires companies to document and disclose the environmental and social impacts of their supply chains. For companies sourcing botanicals from regions with limited traceability infrastructure, meeting these reporting obligations is becoming harder and more expensive.
A broader pattern: Europe is reshoring critical inputs
The push to reshore botanical sourcing does not exist in isolation. Across the pharmaceutical sector, European policymakers are working to reduce dependence on concentrated sources of supply. Approximately 80 per cent of the active pharmaceutical ingredients used in EU medicines originate from India and China, a concentration that the pandemic and subsequent trade volatility exposed as a strategic vulnerability. France’s France 2030 plan has invested in domestic pharmaceutical production capacity, and the European Commission has framed ingredient sovereignty as part of its broader health security agenda. For botanical raw materials, reshoring does not mean replicating tropical field agriculture in European climates. It means deploying controlled-environment cultivation technologies that can produce pharmaceutical-grade plant material independent of geography, season, and soil.
What this looks like in practice
At BotaniX, we operate aeroponic facilities in France that produce over 35 medicinal plant species under controlled conditions. Every parameter, from light spectrum and nutrient delivery to harvest timing and post-harvest processing, is monitored, recorded, and linked to each production batch. The plants are cultivated in France, processed in France, and shipped to European buyers with complete documentation. Our full ingredient catalogue is available online.
For procurement teams, the difference is measurable. Batch rejection rates for field-sourced botanicals can reach 40 per cent due to contamination, potency variation, or documentation gaps. European controlled-environment production addresses each of these failure points at the source rather than managing them downstream through testing and rejection.
The economic case is strengthening
The historical argument against European botanical production was cost. Field-grown material from traditional growing regions has been cheaper on a per-kilogram basis, and for commodity-grade ingredients this remains true. But per-kilogram price is not the same as total cost of sourcing.
When procurement teams account for batch rejection rates, Nagoya compliance verification, CSRD reporting obligations, supplier audit programmes for distant and often opaque supply chains, reformulation costs triggered by inconsistent raw material quality, and production delays caused by climate or trade disruptions, the calculation changes. European controlled-environment production is not competing on commodity price. It is competing on total cost of ownership, and that comparison favors shorter, more controllable, fully documented supply
chains.
Structural, not cyclical
The convergence of climate risk, regulatory pressure, and reporting obligations is not a cycle that will reverse. The EU’s regulatory trajectory is toward more stringent supply chain accountability, not less. Climate volatility in traditional growing regions is accelerating, not stabilizing. And multinational buyers, having experienced repeated supply disruptions, are diversifying toward shorter, auditable chains.
For botanical ingredient buyers, supplier evaluation criteria are evolving. Price and availability remain important, but supply security, regulatory compliance, traceability depth, and sustainability documentation are now weighted factors in procurement decisions. Suppliers who can deliver on all of these dimensions from a European base, with full documentation and independent certification, serve a market that is structurally reshoring.
Yishai Nissan is Co-Founder and COO of BotaniX, a French producer of pharmaceutical-grade botanical ingredients serving the cosmetics, nutraceutical, and pharmaceutical industries.
Frequently Asked Questions
What percentage of pharmaceutical ingredients used in the EU come from outside Europe?
Approximately 80 per cent of active pharmaceutical ingredients (APIs) used in EU medicines originate from India and China, according to EU institutional reports. This concentration has been identified as a strategic vulnerability.
What is the France 2030 plan?
France 2030 is a French government investment program that includes funding for domestic pharmaceutical and ingredient production capacity, as part of a broader European push toward health sovereignty and reduced dependency on extra-European supply chains.
How does controlled-environment cultivation reduce supply chain risk?
By producing plant material indoors under monitored conditions, controlled-environment cultivation eliminates exposure to climate disruption, soil contamination, and seasonal variability. It also provides full-batch documentation from seed to ingredient, supporting compliance with the Nagoya Protocol and the CSRD.
